{"id":7496,"date":"2025-06-24T22:57:16","date_gmt":"2025-06-24T20:57:16","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/"},"modified":"2025-06-24T22:57:17","modified_gmt":"2025-06-24T20:57:17","slug":"la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/","title":{"rendered":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2025\/fda-approves-dupixent-1.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2025\/fda-approves-dupixent-1.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Dupixent (Dupillumab) pour le traitement des patients adultes atteints de pemphigo\u00efde bulle.<\/p>\n<p>L&rsquo;approbation est bas\u00e9e sur les r\u00e9sultats de l&rsquo;\u00e9tude Pivotal Adept Phase 2\/3. Les patients atteints de pemphigo\u00efde bulleux mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re ont \u00e9t\u00e9 assign\u00e9s au hasard pour recevoir 300 mg de Dupixent (53 individus) ou un placebo (53 individus) ajout\u00e9s \u00e0 des corticost\u00e9ro\u00efdes oraux standard en soins. \u00c0 36 semaines, 18,3% des patients trait\u00e9s par Dupixent ont connu une r\u00e9mission de maladie soutenue contre 6,1% avec un placebo. De plus, 38,3% des patients trait\u00e9s par Dupixent ont atteint une r\u00e9duction des d\u00e9mangeaisons cliniquement significative contre 10,5% avec un placebo. Enfin, la dose de corticost\u00e9ro\u00efdes orale cumulative m\u00e9diane \u00e9tait plus faible avec Dupixent contre le placebo (2,8 contre 4,1 grammes).<\/p>\n<p>Les \u00e9v\u00e9nements ind\u00e9sirables les plus courants (\u2265 2%) observ\u00e9s chez les patients trait\u00e9s par dupixent comprenaient l&rsquo;arthralgie, la conjonctivite, la vision floue, les infections virales de l&rsquo;herp\u00e8s et la k\u00e9ratite. Un patient trait\u00e9 par Dupixent a signal\u00e9 une pustulose exanth\u00e9mateuse g\u00e9n\u00e9ralis\u00e9e aigu\u00eb.<\/p>\n<p>\u00ab\u00a0Jusqu&rsquo;\u00e0 pr\u00e9sent, le traitement du pemphigo\u00efde bulle \u00e9tait tr\u00e8s difficile pour les patients \u00e2g\u00e9s aux prises avec l&rsquo;impact d\u00e9bilitateur des cloques et des l\u00e9sions, et des conditions potentiellement comorbides\u00a0\u00bb, a d\u00e9clar\u00e9 Alyssa Johnsen, MD, Ph.D., dans un communiqu\u00e9.<\/p>\n<p>\u00ab\u00a0En s&rsquo;adressant \u00e0 deux moteurs centraux de l&rsquo;inflammation sous-jacente de type 2 qui contribue au pemphigo\u00efde bulleux, Dupixent est le premier m\u00e9dicament cibl\u00e9 \u00e0 permettre aux patients le potentiel d&rsquo;atteindre une r\u00e9mission soutenue et de r\u00e9duire les d\u00e9mangeaisons.\u00a0\u00bb<\/p>\n<p>L&rsquo;approbation de Dupixent pour cette indication a \u00e9t\u00e9 accord\u00e9e \u00e0 Sanofi et Regeneron.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Dupixent (Dupillumab) pour le traitement des<\/p>\n","protected":false},"author":1,"featured_media":7497,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[321,5777,5775,447,5776,8],"class_list":["post-7496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-approuve","tag-bulleux","tag-dupixent","tag-fda","tag-pemphigoide","tag-pour","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Dupixent (Dupillumab) pour le traitement des\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T20:57:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T20:57:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux\",\"datePublished\":\"2025-06-24T20:57:16+00:00\",\"dateModified\":\"2025-06-24T20:57:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\"},\"wordCount\":303,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg\",\"keywords\":[\"approuve\",\"bulleux\",\"Dupixent\",\"FDA\",\"pemphigo\u00efde\",\"pour\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\",\"name\":\"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg\",\"datePublished\":\"2025-06-24T20:57:16+00:00\",\"dateModified\":\"2025-06-24T20:57:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg\",\"width\":1280,\"height\":853,\"caption\":\"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org","og_description":"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Dupixent (Dupillumab) pour le traitement des","og_url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/","og_site_name":"RVH-Synergie","article_published_time":"2025-06-24T20:57:16+00:00","article_modified_time":"2025-06-24T20:57:17+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux","datePublished":"2025-06-24T20:57:16+00:00","dateModified":"2025-06-24T20:57:17+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/"},"wordCount":303,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg","keywords":["approuve","bulleux","Dupixent","FDA","pemphigo\u00efde","pour"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/","url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/","name":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg","datePublished":"2025-06-24T20:57:16+00:00","dateModified":"2025-06-24T20:57:17+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/06\/1750798636_La-FDA-approuve-le-Dupixent-pour-le-pemphigoide-bulleux.jpg","width":1280,"height":853,"caption":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-le-dupixent-pour-le-pemphigoide-bulleux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"La FDA approuve le Dupixent pour le pemphigo\u00efde bulleux"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/7496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=7496"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/7496\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/7497"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=7496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=7496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=7496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}